Radioactive antibody combo aims to beat back tough hodgkin lymphoma
NCT ID NCT04871607
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a new approach for people with Hodgkin lymphoma that has not responded to treatment or has come back. It combines a radioactive antibody (yttrium-90 labeled anti-CD25) with standard BEAM chemotherapy before a stem cell transplant. The goal is to see if this combination can improve how long people stay cancer-free. The study plans to enroll 33 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Yttrium-90 labeled anti-CD25 monoclonal antibody (basiliximab) combined with BEAM chemotherapy (carmustine, etoposide, cytarabine, melphalan)
What this could lead to
If successful, this could improve the chance of long-term remission for people with Hodgkin lymphoma that has not responded to or returned after standard treatment.
What could go wrong
This is a small, early-phase trial (33 people) with no control group, so results may not apply broadly. The treatment includes high-dose chemo and radiation, which can cause serious side effects like infections and organ damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact